Xuanhan County Peoples Hospital

A review.Cardiovascular diseases remain a critical global health challenge, necessitating advanced diagnostic tools for early detection and monitoring.This review comprehensively examines the emerging field of photoelectrochem. (PEC) sensing strategies for cardiovascular biomarker detection, highlighting recent technol. innovations and applications.We analyze various PEC detection mechanisms, including direct label-free approaches and indirect amplification methods, emphasizing their roles in achieving enhanced sensitivity and specificity.The review explores crucial developments in semiconductor nanostructures, composite materials, and two-dimensional materials, detailing their integration into sensing platforms.Particular attention is given to recognition elements, including antibodies and aptamers, and their optimization for specific biomarker detection.Recent advances in signal amplification strategies, such as enzymic labeling and nanoparticle-based enhancement, are discussed in the context of achieving clin. relevant detection limits.The review also addresses current tech. challenges, including matrix effects in biol. samples and long-term stability issues, while highlighting promising solutions through materials engineering and device design.Understanding these aspects is crucial for advancing PEC biosensor development toward practical clin. applications.

The purpose of this article is to discuss the use, comparative efficacy, and research progress of radiofrequency ablation (RFA), alone or in combination with other therapies, for the treatment of hepatocellular carcinoma (HCC).

To search and summarize the basic and clinical studies of RFA in recent years.

RFA is one of the radical treatment methods listed in the guidelines for the diagnosis and treatment of HCC. It has the characteristics of being minimally invasive and safe and can obtain good local tumor control, and it can improve the local immune ability, improve the tumor microenvironment and enhance the efficacy of chemotherapy drugs. It is commonly used for HCC treatment before liver transplantation and combined ALPPS and hepatectomy for HCC. In addition, the technology of RFA is constantly developing. The birth of noninvasive, no-touch RFA technology and equipment and the precise RFA concept have improved the therapeutic effect of RFA.

RFA has good local tumor control ability, is minimally invasive, is safe and has other beneficial characteristics. It plays an increasingly important role in the comprehensive treatment strategy of HCC. Whether RFA alone or combined with other technologies expands the surgical indications of patients with HCC and provides more benefits for HCC patients needs to be determined.